infusion of glucose at rates approximating EGP enhances glucose disposal but does not cause hypoglycemia. Am J Physiol Endocrinol Metab 285: E280-E286, 2003; 10.1152/ ajpendo.00055.2003.-Portal infusion of glucose at rates approximating endogenous glucose production (EGP) causes paradoxical hypoglycemia in wild-type but not GLUT2 null mice, implying activation of a specific portal glucose sensor. To determine whether this occurs in humans, glucose containing [3-3 H]glucose was infused intraduodenally at rates of 3.1 mg ⅐ kg
Ϫ1
infusions, reaching a peak of 10 Ϯ 2 and 18 Ϯ 5 U/ml, respectively, by 2 h. Insulin concentrations then fell back to concentrations that no longer differed by study end (7 Ϯ 1 vs. 8 Ϯ 1 U/ml). This resulted in comparable suppression of EGP by study end (0.84 Ϯ 0.2 and 0.63 Ϯ 0.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 ). Glucose disappearance was higher (P Ͻ 0.01) during the final hour of the 3.1 than 1.55 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id infusion (4.47 Ϯ 0.2 vs. 2.6 Ϯ 0.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 ), likely because of the slightly, but not significantly, higher glucose and insulin concentrations. We conclude that, in contrast to mice, selective portal glucose delivery at rates approximating EGP does not cause hypoglycemia in humans. portal signal; splanchnic glucose extraction; glucose uptake; endogenous glucose production PREVIOUS STUDIES IN ANIMALS (6, 11, 13, 15, 17, 18) and humans (9, 21) have provided compelling evidence for the existence of a portal glucose "sensor" that regulates both hepatic and peripheral glucose uptake. Enteric absorption of glucose causes concentrations to be higher in the portal vein than in the systemic circulation (2, 15) . The resultant portal-to-hepatic venous glucose gradient has been reported to enhance hepatic glucose uptake and inhibit extrahepatic glucose disposal (2, 3, 10, 15, 18) . Both hyperglycemia and hyperinsulinemia are required for the portal glucose "signal" to be detected (2, 10, 18) . ACh activates and vagotomy or hepatic denervation abolishes the portal glucose signal, implying a neural origin (1, 23) . In addition, infusion of glucose into the portal vein dampens the counterregulatory response to systemic hypoglycemia (14) . Taken together, these data suggest that activation of the portal glucose sensor minimizes changes in portal and systemic glucose concentration.
The mechanism by which the portal vein senses glucose is an area of active investigation. Burcelin et al. (5) (6) (7) , in an elegant series of experiments, have strongly implicated GLUT2 transporters in this process. They have shown that infusion of glucose in the portal vein of mice at a rate that approximated basal endogenous glucose production (EGP) markedly increased peripheral glucose clearance (7). This effect did not occur in mice in whom the GLUT2 transporter was knocked out and could be abolished by concurrent infusion of either somatostatin or the glucagon-like peptide (GLP)-1 antagonist exendin (5-7). In addition to providing interesting mechanistic insights, these studies were both surprising and provocative since intraportal glucose infusion caused a paradoxical fall in the plasma glucose concentration to hypoglycemic levels (5) (6) (7) .
We have demonstrated previously that peripheral and splanchnic glucose uptake were the same in nondiabetic humans when glucose was infused intraduodenally or intravenously at a rate of 4 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 (24) . However, in those experiments, glucose was clamped at ϳ150 mg/dl and insulin at ϳ400 pmol/l to stimulate hepatic and peripheral glucose uptake. Somatostatin had to be given to inhibit endogenous insulin secretion so as to ensure comparable portal insulin concentrations on both occasions. Somatostatin also has been given for the same reason in the animal experiments that have shown that intraportal glucose infusion decreases rather than increases extrahepatic glucose uptake (2, 8, 10, 18) . Therefore, it is possible that use of somatostatin in ours and other investiga-tors' experiments either dampened or ablated the response of the putative portal glucose sensor. Alternatively, the response to intraportal glucose delivery in dogs and humans may differ from that in mice.
The present experiments sought to address this question by testing the hypothesis that intraduodenal infusion of glucose (and its resultant selective delivery in the portal vein) at rates approximating EGP results in hypoglycemia in humans. We further hypothesized that hypoglycemia (if it occurred) would be the result of a combination of inappropriately elevated rates of glucose uptake and inappropriately suppressed rates of EGP. To examine this question, we infused glucose at rates of 1.55 and 3.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id for 7 h and compared the results with those observed when either saline or trace (0.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 ) amounts of glucose were infused intraduodenally for the same length of time. We report that intraduodenal glucose infusion at rates approximating EGP does not cause hypoglycemia in humans.
RESEARCH DESIGN AND METHODS

Subjects.
After approval from the Mayo Institutional Review Board, 14 nondiabetic subjects gave informed written consent to participate in the study. All subjects were in good health and were at a stable weight. None of the volunteers had a first-degree relative with a history of diabetes. Subjects were on no medications other than oral contraceptives, estrogen, or thyroxin replacement. All subjects were instructed to follow a weight maintenance diet containing 55% carbohydrate, 30% fat, and 15% protein for at least 3 days before study. Age, gender, body mass index, lean body mass, and percent body fat of the volunteers are given in Table 1 .
Experimental design. Each subject was studied on two occasions separated by at least 1 wk. On the afternoon before each study, subjects were taken to the fluoroscopy unit on the Mayo General Clinical Research Center where an 8-Fr Flexiflo enteral feeding tube (Ross Laboratories, Columbus, OH) was passed under fluoroscopic guidance via the nasopharynx in the fourth part of the duodenum. On average, 15 min were required for tube placement and Ͻ2 min of fluoroscopy for verification of the tube's location. The subjects were then admitted to the Mayo General Clinical Research Center where they ate a standard 10 kcal/kg meal (55% carbohydrate, 30% fat, and 15% protein) between 1700 and 1730. The subjects took nothing by mouth after supper with the exception of small amounts of water until the end of study. At 0430 on the following morning, a forearm vein was cannulated with an 18-gauge needle to allow infusion of [6,6- 2 H2]glucose. In addition, an 18-gauge cannula was inserted retrogradely in a vein of the contralateral hand. The hand was then placed in a Plexiglas box maintained at 55°C to allow sampling of arterialized venous blood. At 0500, a primed continuous infusion of [6,6- 2 H2]glucose was started and continued until the end of the study. At ϳ0630, the position of the nasoduodenal tube was confirmed by a portable abdominal radiography. At 0800 (0 min), a primed (12 Ci) continuous infusion (0.12 Ci/min) of [3- 3 H]glucose was infused in the duodenum via the nasoduodenal tube for the next 7 h. The [3- 3 H]glucose infusion also contained unlabeled glucose. In five subjects, glucose was infused in the duodenum at a rate of 3.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 on one occasion and 0.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 on the other occasion. In nine subjects, glucose was infused in the duodenum at a rate of 1.55 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 on one occasion and either saline (n ϭ 4) or glucose (n ϭ 5) at a rate of 1.22 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 (in error rather than saline) on the other occasion. The results of 1.22 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 infusion did not differ substantially from the 1.55 mg ⅐ kg Ϫ1 ⅐ min
Ϫ1
infusion and therefore are not presented as part of the current study but are available upon request. In addition, because results did not differ during the 0.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id or saline alone infusions, these results were combined for purposes of analysis. Blood samples were collected at Ϫ180, Ϫ30, 0, 60, 120, 180, 210, 220, 230, 240, 270, 300, 330, 360, 390, and 420 min for analysis of tracer, hormone, and substrate concentrations.
Analytical determinations. Arterialized venous plasma samples were placed on ice, centrifuged at 4°C, and separated and stored at Ϫ20°C until assay. C-peptide and glucagon concentrations were measured using reagents purchased from Linco Research (St. Louis, MO). Insulin and growth hormone were measured using a chemiluminescence assay with reagents obtained from Beckman (Access Assay; Beckman, Chaska, MN). Plasma glucose concentration was measured using a Yellow Springs glucose analyzer. Plasma [3- 3 H]glucose specific activity and [6,6-2 H2]glucose enrichment were measured by liquid scintillation counting and gas chromatography-mass spectrometry (16, 19) . Percent body fat and fat-free mass were measured using a dual-energy X-ray absorptiometry scan QDR4500 with fan scan technology.
Calculations. Rates of glucose appearance and disappearance were calculated using Steele's non-steady-state equations (22) . A pool volume of 200 ml/kg and a pool fraction of 0.65 were assumed. The systemic rate of appearance of the intraduodenally infused [3- 3 H]glucose was also calculated using Steele's steady-state equations in which the plasma [3- 3 H]glucose concentration was substituted for the unlabeled glucose concentration (4). The systemic rate of appearance of [3- 3 H]glucose (in dpm ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was divided by the specific activity of the intraduodenally infused glucose (in dpm/mg) to convert the rates to milligrams per kilogram per minute. EGP was calculated by subtracting the systemic rate of appearance of the intraduodenally infused glucose from the total rate of appearance of glucose. Initial splanchnic glucose extraction was calculated as 1 minus the systemic rate of appearance of H]glucose divided by the intraduodenal infusion rate of [3- 3 H]glucose. Statistical analysis. Data in the text and Figs. 1-3 are expressed as means Ϯ SE. All rates are expressed as milligrams per kilogram total body weight per minute. ANOVA followed by a signed-rank test was used to compare the results of the different studies. A P value Ͻ0.05 was considered statistically significant. (Fig. 1B) 
Insulin concentrations fell during the 7 h of the 0/0.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id study (to 3 Ϯ 1 U/ml). In contrast, insulin increased (P Ͻ 0.05) during the 1.55 and 3.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 infusions, reaching a peak of 10 Ϯ 2 and 18 Ϯ 5 U/ml, respectively, by 2 h (P ϭ 0.07; 1.55 vs. 3.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 infusions). Insulin concentrations then fell back to concentrations that no longer differed by study end (7 Ϯ 1 vs. 8 Ϯ 1 U/ml). Of note, the plasma insulin concentrations of one individual were three SDs greater than those of the other subjects in that group both before and during the 1.55 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 infusion and therefore were excluded from analysis.
Fasting plasma C-peptide concentrations ( Fasting plasma glucagon concentrations (Fig. 1D ) did not differ on the 0/0.1, 1.55, and 3.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id study days (134 Ϯ 13 vs. 146 Ϯ 8 vs. 115 Ϯ 6 pg/ml). Glucagon concentrations fell (P Ͻ 0.01) during the 3.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id infusion to 100 Ϯ 6 ng/l and during the 1.55 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 infusion to 128 Ϯ 6 ng/l and remained unchanged during the 0/0.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id infusion (125 Ϯ 8). Growth hormone concentrations also did not differ on the three study days either before or during the intraduodenal infusions (data not shown).
Plasma [6,6- Systemic rate of appearance of intraduodenally infused glucose, EGP, and glucose disappearance. The systemic rate of appearance of intraduodenally infused glucose increased during the first 3 h of the 1.55 and 3.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id infusions, reaching a plateau thereafter (Fig. 3A) . The appearance of intraduodenal 
DISCUSSION
Portal venous and arterial glucose concentrations do not differ in the fasting state, with both being lower than those in the hepatic vein (2, 15) . Ingestion of a carbohydrate-containing meal results in a selective increase in the portal venous glucose concentration, thereby increasing the portal venous-to-hepatic venous glucose gradient (2, 15) . This gradient is further accentuated by the increase in hepatic glucose uptake resulting from the accompanying postprandial increase in portal insulin concentrations (2, 3, 9-11, 18, 20, 23) . Multiple studies have established that hepatic glucose uptake at any given insulin concentration is greater in the presence than in the absence of a portal venous-tohepatic venous glucose gradient, implying the existence of so-called portal glucose "sensors" (2, 3, 9-11, Fig. 3 . Systemic rate of appearance of intraduodenally infused glucose (A), endogenous glucose production (B), and glucose disappearance (C) observed before and during intraduodenal infusion of glucose at a rate of either 0/0.1, 1.55, or 3.1 mg ⅐ kg Ϫ1 ⅐ min
Ϫ1
. The intraduodenal infusions were started at time 0. 18, 20, 23) Studies in dogs have shown that activation of these receptors also results in a compensatory decrease in extrahepatic glucose uptake (3, 10) . These experiments, however, employed relatively high portal venous glucose infusion rates to create gradients similar to those observed after food ingestion. Therefore, the reports by Burcelin et al. (5-7) that infusion of glucose in the portal vein of mice at rates approximating EGP caused marked hypoglycemia were surprising. The demonstration that this response did not occur when portal GLUT2 transporters were knocked out was particularly intriguing, since it implied that hypoglycemia was caused by selective activation of a portal venous glucose sensor (6) .
The present experiments were undertaken to determine whether low rates of delivery of glucose in the portal vein also resulted in hypoglycemia. To do so, we infused glucose in the duodenum at rates of 1.55 and 3.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 . We chose these rates since we wanted to bracket the normal postabsorptive rate of EGP (i.e., ϳ2 mg⅐ kg Ϫ1 ⅐ min Ϫ1 ). Both infusions stimulated insulin secretion; however, in contrast to what was observed in mice (5-7), glucose concentrations rose rather than fell. The increase in glucose was evident whether considered as the change from the basal value or compared with the glucose concentrations observed over the same interval during the 0/0.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id glucose infusions. The rise in glucose concentration continued until glucose disappearance increased sufficiently to equal the sum of the systemic rate of appearance of the intraduodenally infused glucose and EGP. The increase in glucose and insulin concentrations during the 1.55 and 3.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 infusions resulted in equivalent suppression of EGP. However, despite comparable glucose and insulin concentrations, glucose disappearance increased more during the 3.1 than during the 1.55 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id infusions, thereby compensating for the higher systemic rate of appearance of the intraduodenal glucose. Thus selective intraportal infusion of glucose in humans did not cause hypoglycemia but may have enhanced glucose disposal.
It is interesting to speculate why glucose disappearance was higher during the 3.1 than during the 1.55 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id infusion. Burcelin et al. (6, 7) observed greater rates of glucose clearance during intraportal than during intravenous glucose infusion in mice. This effect did not occur in the GLUT2 knockout mice, suggesting a role for a portal glucose sensor (6) . Activation of a portal glucose sensor that in turn enhanced extrahepatic glucose disposal also may have occurred in the present experiments. The higher rates of glucose disappearance during the 3.1 than during the 1.5 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id infusion despite comparable glucose, insulin, and C-peptide concentrations is consistent with this possibility. On the other hand, we have previously shown that glucose disappearance was the same when glucose was infused intraduodenally or intravenously in nondiabetic volunteers at a rate of 4.0 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 (24) . If the higher rates of glucose disappearance were mediated by a glucose sensor, this would imply a narrow dose-response curve, since this effect was absent during the current 1.55 and the past 4.0 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 glucose id infusions but present during the current 3.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 glucose infusion. On the other hand, glucose was clamped at ϳ150 mg/dl in our previous experiments, and somatostatin was infused to inhibit endogenous insulin secretion (24) . Because somatostatin, perhaps by inhibiting GLP-1 secretion (12), blunts the "portal signal" in mice (5), our previous experiments could have missed a stimulatory effect of intraportal glucose delivery on glucose disappearance (24) .
Alternatively, the higher rate of glucose disappearance during the 3.1 than during the 1.55 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id infusion could have been because of the residual effect of antecedent higher insulin concentration combined with the slightly (but not significantly) higher glucose concentration. As is evident from Fig. 1 , both insulin and C-peptide concentrations tended to be higher during the 3.1 than during the 1.55 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id infusions, with the differences being most marked immediately after the start of the intraduodenal infusions. Glucose disappearance more closely reflects interstitial than plasma insulin concentrations, and a change in interstitial insulin concentration lags behind a change in plasma insulin concentration (25) . Therefore, the higher plasma insulin concentrations during the first few hours of the 3.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id infusion could have resulted in higher rates of glucose disappearance several hours later. The present experiments therefore leave open the possibility that selective intraportal infusion at rates bracketing EGP may enhance extrahepatic glucose uptake in humans.
We infused glucose at rates of either 0 (i.e., saline alone) or 0.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 as control experiments. We included these control experiments since we wanted to be able to determine whether a fall in glucose concentration (if observed) during the 1.55 and 3.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id glucose infusions was greater than that which occurred with fasting alone. We infused [3- 3 H]glucose and carrier unlabeled glucose at a rate of 0.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 in five of the subjects and [3- 3 H]glucose with saline alone in four of the subjects. We included the saline-alone experiments since we were concerned that infusion of even a small amount of glucose in the duodenum might evoke an enteral signal, thereby obscuring differences that might occur with the higher intraduodenal glucose infusion rates. This was not the case since the results were the same during infusion of either the 0 (saline) or 0.1 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id infusions. Bureclin et al. (5) reported that the GLP-1 antagonist exendin-(9-36) prevented hypoglycemia during intraportal glucose infusion in mice, whereas GLP-1 infusion did not. This suggested that the presence of basal levels of GLP-1 acting alone or in combination with other incretin hormones is required for activation of the portal signal in mice. We presume that incretin levels either remained constant or increased slightly during the intraduodenal glucose infusions. Therefore, the lack of hypoglycemia during the intraduodenal glucose infusions is unlikely to be because of a deficiency of incretin hormones.
The present experiments have several limitations. We assumed that essentially all of the glucose that was infused in the duodenum was absorbed within the small intestine or upper colon. If some of the glucose was absorbed by the distal colon, then the rate of glucose entry in the portal circulation may have been slightly lower than the rate of intraduodenal infusion, since at least a portion of the venous drainage of the distal colon directly enters the systemic circulation. However, we doubt if substantial amounts of glucose were absorbed by the distal colon, since we infused glucose in the duodenum at a rate that was well below the absorptive capacity of the small intestine and since we would anticipate that the majority of glucose reaching the colon would be metabolized by colonic bacteria rather than absorbed (26, 27). Glucose was infused in the duodenum rather than directly in the portal vein since the latter is not feasible in healthy human volunteers. It therefore remains possible that activation of other control mechanisms (e.g., enteric nervous system, enteric hormone secretion) prevented the development of hypoglycemia. Future studies will be required to address this question.
In summary, intraduodenal glucose infusion at rates bracketing normal EGP does not cause hypoglycemia in nondiabetic humans. Rather, glucose and insulin concentrations increase slightly. The higher glucose and insulin concentrations appropriately suppress EGP and stimulate glucose disappearance, thereby minimizing the rise in glucose concentration. On the other hand, the higher rates of glucose disappearance during the 3.1 than during the 1.55 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 id infusion in the presence of slightly but not significantly higher glucose and insulin concentrations is consistent with, but does not prove the existence of, a portal signal in humans that enhances extrahepatic glucose disposal. Future studies will be required to specifically address this question in humans.
